Table 1.
Clinical description and severe acute respiratory syndrome (SARS) coronavirus (CoV) dissemination to multiple organs in 19 patients who died of probable SARS.
| Illness or treatment duration, days | Postmortem tissue SARS CoV RT-PCR resultsa | |||||||||||||
|
|
|
|||||||||||||
| Patient no. (sex/age in years) | Comorbidities | Illness | Ventilation | Ribavirin | Steroidsb | Lung | Liver | Spleen | Kidney | Small bowel | Large bowel | Lymph nodes | Heart | Muscle |
| A109 (F/88) | HTN, CVD, osteoporosis | 5 | DNI | 0 | 0 | 1.0 × 1010 | NA | NA | NA | NA | NA | NA | 1.6 × 104 | — |
| A53 (M/62) | Rectal cancer, HTN, hypercholesterolemia | 10 | 5 | 3 | 4 | 5.3 × 107 | 6.0 × 103 | 1.3 × 104 | — | 2.7 × 109 | 5.9 × 104 | NA | 2.6 × 104 | 2.8 × 104 |
| A108 (F/67) | None | 10 | 0 | 0 | 2 | 3.3 × 105 | NA | NA | NA | NA | NA | NA | 1.0 × 104 | — |
| A52 (M/76) | Type 2 DM, CAD, HTN | 11 | 4 | 4 | 0 | 3.8 × 109 | 1.8 × 104 | 7.2 × 105 | 3.7 × 104 | NA | NA | NA | — | NA |
| A113 (M/57) | DBL LT for COPD and BOOP, CVD, post LT DM, atrial fibrillation | 14 | 6 | 0 | 6 | 8.8 × 109 | 1.6 × 106 | 1.4 × 105 | 7.4 × 105 | 2.4 × 108 | 3.7 × 108 | 8.9 × 108 | 2.8 × 107 | 1.0 × 104 |
| A51 (F/78) | Type 2 DM, CAD, COPD, hypercholesterolemia | 15 | 5 | 5 | 0 | 1.1 × 109 | 2.8 × 104 | 2.1 × 105 | 1.2 × 105 | 7.3 × 104 | 1.3 × 105 | NA | 3.5 × 105 | — |
| A39 (M/43) | Type 2 DM, HTN | 16 | 4 | 0 | 0 | 6.4 × 108 | 6.0 × 103 | — | NA | NA | NA | NA | NA | NA |
| A71 (M/78) | Type 2 DM, HTN, hypercholesterolemia | ⩾18 | ⩾4 | >2 | >7 | 5.7 × 105 | — | — | — | 2.7 × 105 | 5.1 × 104 | 9.5 × 104 | — | — |
| A67 (M/63) | Hypercholesterolemia, CVD | 20 | 12 | 16 | 14 | 2.5 × 107 | — | 6.1 × 104 | — | 3.3 × 105 | 6.3 × 106 | 2.8 × 104 | 3.2 × 104 | — |
| A68 (F/78) | Type 2 DM, HTN, hypercholesterolemia | 23 | 18 | 11 | 18 | 4.9 × 105 | 5.0 × 104 | 3.6 × 104 | 5.9 × 104 | 4.7 × 106 | 7.7 × 107 | 4.2 × 105 | 6.8 × 104 | — |
| A57 (F/73) | HTN, hypercholesterolemia | 24 | DNI | 8 | 11 | 3.6 × 105 | — | — | — | — | 6.1 × 105 | 1.5 × 104 | — | — |
| A154 (M/45) | None | 24 | 12 | 0 | 10 (+ IFN 10) | 5.5 × 104 | 1.8 × 104 | 8.7 × 103 | 4.3 × 103 | 2.7 × 103 | 5.3 × 103 | 7.1 × 104 | — | — |
| A63 (F/99) | Osteoarthritis | 25 | DNI | 7 | 0 | 5.0 × 104 | — | — | — | 1.7 × 104 | 6.1 × 104 | — | — | — |
| A159 (F/81) | Spinal tumor | 27 | 24 | 0 | 18 (+ IFN 11) | 2.0 × 104 | — | 1.3 × 104 | 8.9 × 103 | 1.2 × 104 | 2.9 × 105 | 7.0 × 104 | — | — |
| A69 (M/44) | None | 29 | 18 | 18 | 17 | 7.6 × 104 | — | 4.8 × 104 | — | 9.2 × 105 | — | 6.1 × 105 | — | — |
| A72 (F/79) | Type 2 DM, HTN, hypercholesterolemia | 29 | DNI | 7 | 9 | 2.1 × 105 | — | — | — | 1.3 × 104 | — | — | — | — |
| A150 (M/68) | CVD | 34 | DNI | NA | NA | 2.4 × 104 | — | — | — | — | — | 2.0 × 104 | — | — |
| A164 (F/51) | Borderline DM | 43 | 31 | 0 | 22 (+ IFN 20 and IVIG) | 1.5 × 105 | — | — | — | — | 1.4 × 104 | — | — | — |
| A173 (F/77) | Asthma, HTN | 51 | 43 | 0 | 5 | 2.9 × 105 | — | — | — | — | — | — | — | — |
NOTE. BOOP, bronchiolitis obliterans and organizing pneumonia; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CVD, cerebral vascular disease; DBLLT, double lung transplant; DM, diabetes mellitus; DNI, do not intubate; HTN, hypertension; IFN, interferon; IVIG, intravenous immunoglobulin; NA, not available.
a
Positive results are denoted by their SARS CoV levels, in copies/g; minus signs (—) denote negative results.
b
Supplementary treatments and their duration in days are shown in parentheses.